Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19

Author(s): Firoz Anwar*, Hisham N. Altayb, Fahad A. Al-Abbasi, Vikas Kumar and Mohammad A. Kamal*

Volume 27, Issue 9, 2021

Published on: 25 January, 2021

Page: [1202 - 1210] Pages: 9

DOI: 10.2174/1381612827666210125121954

Price: $65

Abstract

Background: The spike (S) glycoprotein of SARS corona virus (SARS-CoV-2) and human Angiotensin- converting enzyme 2 (ACE2), are both considered the key factors for the initiation of virus infection. The present work is an effort for computational target to block the spike proteins (S) and ACE2 receptor proteins with Macrolide antibiotics like Azithromycin, (AZM), Clarithromycin (CLAM) and Erythromycin (ERY) along with RNA-dependent RNA polymerase (RdRp).

Methods: Three-dimensional structure of the SARS-CoV-2RdRp was built by the SWISS-MODEL server, the generated structure showed 96.35% identity to the available structure of SARS-Coronavirus NSP12 (6NUR), for model validity, we utilized the SWISS-model server quality parameters and Ramachandran plots.

Results: These compounds were able to block the residues (Arg553, Arg555, and Ala558) surrounding the deep grove catalytic site (Val557) of RdRp and thus plays an important role in tight blocking of enzyme active site. Reference drug Remdesivir was used to compare the docking score of antibiotics with RdRp. Docking value exhibited good binding energy (-7.7 up to -8.2 kcal/mol) with RdRp, indicating their potential as a potent RdRp inhibitor. Interaction of CLAM and ERY presented low binding energy (-6.8 and -6.6) with the ACE2 receptor. At the same time, CLAM exhibited a good binding affinity of -6.4 kcal/mol, making it an excellent tool to block the attachment of spike protein to ACE2 receptors. Macrolides not only affected the attachment to ACE2 but also blocked the spike proteins further, consequently inhibiting the internalization in the host cell. Three Alkyl bonds between Arg555, Ala558, and Met542 by CLAM and two Alkyl bonds of Arg624 and Lys621 by ERY plays an important role for RdRp inactivation, that can prevent the rise of newly budded progeny virus. These macrolides interacted with the main protease protein in the pocket responsible for the dimerization and catalytic function of this protein. The interaction occurred with residue Glu166, along with the catalytic residues (Tyr343, and His235) of Endoribonuclease (NSP15) protein.

Conclusion: The present study gives three-way options either by blocking S proteins or ACE2 receptor proteins or inhibiting RdRp to counter any effect of COVID-19 by macrolide and could be useful in the treatment of COVID-19 till some better option available.

Keywords: COVID-19, spike proteins, RNA dependent, RNA polymerase, ACE2, macrolides, dimerization and catalytic function.

« Previous Next »
[1]
Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
WHO; Coronavirus disease 2009 (COVID-19): situation report. Organization. Available at:. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
[3]
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382(21): 1969-73.
[http://dx.doi.org/10.1056/NEJMp2005630] [PMID: 32227757]
[4]
Heiser K, McLean PF, Davis CT, et al. Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2. bioRxiv 2020.
[5]
Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica 2020; 44.
[http://dx.doi.org/10.26633/RPSP.2020.40] [PMID: 32256547]
[6]
Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4)
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[7]
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006; 6(2): 67-9.
[http://dx.doi.org/10.1016/S1473-3099(06)70361-9] [PMID: 16439323]
[8]
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1)
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[9]
Balzarini J, Keyaerts E, Vijgen L, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 2006; 72(1): 20-33.
[http://dx.doi.org/10.1016/j.antiviral.2006.03.005] [PMID: 16675038]
[10]
Wang Y, Cui R, Li G, et al. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res 2016; 125: 1-7.
[http://dx.doi.org/10.1016/j.antiviral.2015.11.003] [PMID: 26585243]
[11]
Zhou N, Pan T, Zhang J, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016; 291(17): 9218-32.
[http://dx.doi.org/10.1074/jbc.M116.716100] [PMID: 26953343]
[12]
Barrows NJ, Campos RK, Powell ST, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 2016; 20(2): 259-70.
[http://dx.doi.org/10.1016/j.chom.2016.07.004] [PMID: 27476412]
[13]
Ohe M, Shida H, Jodo S, et al. Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends 2020; 14(2): 159-60.
[http://dx.doi.org/10.5582/bst.2020.03058] [PMID: 32249257]
[14]
Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo) 2019; 72(10): 759-68.
[http://dx.doi.org/10.1038/s41429-019-0204-x] [PMID: 31300721]
[15]
Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24(8): 1634-43.
[http://dx.doi.org/10.1038/sj.emboj.7600640] [PMID: 15791205]
[16]
Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res 2019; 105: 93-116.
[http://dx.doi.org/10.1016/bs.aivir.2019.08.002] [PMID: 31522710]
[17]
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[18]
Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020.
[http://dx.doi.org/10.1016/j.cell.2020.11.032]
[19]
Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 2018; 46(W1)W296-303
[http://dx.doi.org/10.1093/nar/gky427] [PMID: 29788355]
[20]
Furnham N, Doré AS, Chirgadze DY, de Bakker PI, Depristo MA, Blundell TL. Knowledge-based real-space explorations for low-resolution structure determination. Structure 2006; 14(8): 1313-20.
[http://dx.doi.org/10.1016/j.str.2006.06.014] [PMID: 16905105]
[21]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367(6485): 1444-8.
[http://dx.doi.org/10.1126/science.abb2762] [PMID: 32132184]
[22]
Berman HM, Battistuz T, Bhat TN, et al. The protein data bank Acta Crystallogr D Biol Crystallogr 2002; 58(Pt 6 No 1): 899-907..
[http://dx.doi.org/10.1107/S0907444902003451 ] [PMID: 12037327]
[23]
Kim S, Thiessen PA, Bolton EE, et al. PubChem substance and compound databases. Nucleic Acids Res 2016; 44(D1): D1202-13.
[http://dx.doi.org/10.1093/nar/gkv951] [PMID: 26400175]
[24]
BIOVIA DS. Discovery studio visualizer. San Diego, CA, USA 2017.
[25]
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 2015; 43(W1)
[http://dx.doi.org/10.1093/nar/gkv315] [PMID: 25873628]
[26]
Braz HLB, Silveira JAM, Marinho AD, et al. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Int J Antimicrob Agents 2020; 56(3)
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106119] [PMID: 32738306]
[27]
Gul S, Ozcan O, Asar S, Okyar A, Barıs I, Kavakli IH. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. J Biomol Struct Dyn 2020; 1-20.
[http://dx.doi.org/10.1080/07391102.2020.1802346] [PMID: 32752938]
[28]
Zhang L, Zhou R. Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase
[29]
Lung J, Lin YS, Yang YH, et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol 2020; 92(6): 693-7.
[http://dx.doi.org/10.1002/jmv.25761] [PMID: 32167173]
[30]
Behl T, Kaur I, Bungau S, et al. The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci 2020; 257.
[http://dx.doi.org/10.1016/j.lfs.2020.118075] [PMID: 32653522]
[31]
Woo H, Shah M, Ahmad B, Choi S. Sequence variation of SARS-CoV-2 spike protein may facilitate stronger interaction with ACE2 promoting high infectivity 2020.
[32]
Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020.
[http://dx.doi.org/10.1016/j.bbrc.2020.02.071] [PMID: 32081428]
[33]
CHAKRABORTY AK. Coronavirus ORF1ab Polyprotein Associated Nsp16 Protein is a RlmE Methyltransferase and May Methylate 21S Mitochondrial rRNA of Most Mells Inhibiting Protein Synthesis. 2020 .
[34]
Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 2020; 92(6): 595-601.
[http://dx.doi.org/10.1002/jmv.25726] [PMID: 32100877]
[35]
Yan R, Zhang Y, Guo Y, Xia L, Zhou Q. Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv 2020.
[36]
Li Z, Tomlinson AC, Wong AH, et al. The human coronavirus HCoV-229E S-protein structure and receptor binding. eLife 2019; 8: 8.
[http://dx.doi.org/10.7554/eLife.51230] [PMID: 31650956]
[37]
Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. American Association for the Advancement of Science 2020; 368: 6489.
[38]
Dai W, Zhang B, Jiang XM, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020; 368(6497): 1331-5.
[http://dx.doi.org/10.1126/science.abb4489] [PMID: 32321856]
[39]
Jewell NP, Lewnard JA, Jewell BL. Predictive Mathematical Models of the COVID-19 Pandemic: Underlying Principles and Value of Projections. JAMA 2020; 323(19): 1893-4.
[http://dx.doi.org/10.1001/jama.2020.6585] [PMID: 32297897]
[40]
Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. J Chem Inf Model 2020; 60(6): 3277-86.
[http://dx.doi.org/10.1021/acs.jcim.0c00179] [PMID: 32315171]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy